Search Results for "Bisphosphonate Dose Esrd"
Original Source: Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) patients have not been investigated. Etidronate, another bisphosphonate, can suppress the extent of coronary artery calcification in chronic hemodialysis patients. The hypothesis of this study is that alendronate can increase bone mineral density and suppress aortic and coronary arter...
Matching Channels
Thimerosal is a mercury-based preservative that has been used for decades in the United States in multi-dose vials (vials containing more than one dose) of some vaccines to prevent the growth of ger...
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...
Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or...
Anthrax Vaccines and Therapeutics
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...
uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused...
Matching News
Bisphosphonate Safety: Some Official Guidance
Sandra Fryhofer, MD, describes a recent FDA review on bisphosphonate safety and offers somewhat reassuring advice. Medscape Internal Medicine
Bisphosphonate link to nonhealing fractures strengthened
US scientists have identified a safety signal between bisphosphonate use and nonhealing femoral fractures, possibly due to the rare side effect, atypical femur fracture.
Bisphosphonate therapy may increase risk of atypical femoral fractures
Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine,...
Rising incidence of atypical femoral fractures linked with bisphosphonate use
NEW YORK (Reuters Health) - Atypical femoral fractures associated with bisphosphonate use, although rare, have increased in incidence over the past 12 years, researchers from Switzerland reported...
Zoledronic acid prevents fractures in men with osteoporosis
N Engl J Med2012;367:1714-23bmj;345/nov06_1/e7471/FIG1F1fig1Zoledronic acid, a bisphosphonate given intravenously at a dose of 5 mg once a year, may reduce the risk of morphometric vertebral...
Atypical Femur Fracture Risk Linked To Bisphosphonate Usage
In a study published Online First by JAMA's Archives of Internal Medicine, Raphael P. H. Meier, M.D., and his team from Geneva's University Hospitals and Faculty of Medicine in Switzerland declare: "C...
Progressing to ESRD: Are All BP Goals the Same?
George Bakris talks to Carmen Peralta about a key study that uses KEEP screening data to identify blood pressure levels in kidney disease that lead to progression to ESRD. Medscape Nephrology
Fracture risk down with adherence to bisphosphonates
(HealthDay)—For patients with an osteoporotic fracture, adherence to bisphosphonate treatment is associated with reduced fracture risk; and for veterans with rheumatoid arthritis, non-adherence to b...
Matching PubMed Articles
The prevalence of long-term bisphosphonate use may be low due to low refill compliance and gaps in treatment. An analysis of the prescription history of 58,674 bisphosphonate users in Denmark found th...
Bisphosphonate use and atypical fractures of the femoral shaft.
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft Original Article, N Engl J Med 2011;364:1728-1737. In Figure 1 (page 1730), the top box should have read, "1,521,131 Women 55 yr or older...
Background: Small retrospective analyses suggest that end-stage renal disease (ESRD) patients do not obtain as much of a survival benefit from an implantable cardioverter-defibrillator (ICD) as non-ES...
Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.
End-stage renal disease (ESRD) with and/or without treatment by hemodialysis (HD) is associated with accelerated atherosclerosis, leading to cardiovascular disease (CVD) including acute coronary syndr...
Numerous studies report a strong association between pretransplant end-stage renal disease (ESRD) duration and diminished transplant outcomes. However, cumulative waiting time may reflect distinct pha...
